Mark S. Berger - Concepedia

Author

Mark S. Berger

The University of Texas MD Anderson Cancer Center

Also Known As

Berger, Mark, M S Berger, MARK BERGER, MARK S. BERGER, Mark Berger, Mark S Berger, Mark S. Berger, Thomas

116

Publications

9.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Actinium Pharmaceuticals (United States)University of Pennsylvania Fred Hutch Cancer Center GlaxoSmithKline (United States)

About

Mark S. Berger is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	2K
2	Health Sciences	2	2	46
3	Engineering	1	1	21
4	Natural Sciences	1	1	24
5	Applied Physics	1	1	21

Mark S. Berger

Publications

8.9K

Citations

H-Index

Page 1

	Year	Citations
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Charles E. Geyer, John Forster, Deborah Lindquist, New England Journal of Medicine	2006	3.4K
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells Gottfried E. Konecny, Mark D. Pegram, Natarajan Venkatesan, Cancer Research Breast OncologyOncologyMedicineReceptor Tyrosine KinaseCell Lines	2006	904
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer, Journal of Clinical Oncology	2001	882
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Mark S. Berger, Gottfried W. Locher, Susanne Saurer, PubMed Gene AmplificationBreast OncologyPathologyNuclear GradingHuman Breast Carcinoma	1988	570
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence Richard A. Larson, Eric L. Sievers, Edward A. Stadtmauer, Cancer	2005	451
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer Henry Gómez, Dinesh Chandra Doval, Miguel A. Chavez, Journal of Clinical Oncology	2008	340
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells Vincent H. J. van der Velden, Jeroen G. te Marvelde, Patricia G. Hoogeveen, Blood	2001	333
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Michael Linenberger, Tom C. Hong, David Flowers, Blood	2001	198
Expression of the <i>c‐erb</i>B‐2 protein in normal and transformed cells William J. Gullick, Mark S. Berger, Paul L. P. Bennett, International Journal of Cancer	1987	197
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies Aaron D. Schimmer, Susan O’Brien, Hagop M. Kantarjian, Clinical Cancer Research	2008	186

Page 1